Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latest filing alerts

Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.

4:02 PM ET 10-Q
Financial Results Noble Romans Inc NROM

Noble Romans Q3 2026 Results: Net Income $84.7K, Down 84.7% YoY

Noble Roman's reported total revenue of $11.27 million for the nine months ended September 30, 2026, a slight increase from the prior year, though net income decreased from $882,839 to $396,072. The company successfully refinanced its debt, moving the majority of its senior loan obligations from current to long-term liabilities.

Key figure
Net income $84.7K · -84.7% YoY
4:02 PM ET 8-K
Financial Results Arrowhead Pharmaceuticals, Inc. ARWR

Arrowhead Pharmaceuticals Financial Results

Arrowhead Pharmaceuticals reported financial results for its fiscal year ended September 30, 2026, highlighting the commercial launch of REDEMPLO for familial chylomicronemia syndrome (FCS). The company reported 950 cumulative prescriptions since launch and announced that the FDA granted plozasiran entry into the STAR pilot program for severe hypertriglyceridemia, qualifying it for a 6-month priority review.

Term
FY2026

“Arrowhead has fundamentally changed over the past 12 months. Where there was once a company that relied solely on great scientific promise, there is now a company that is beginning to translate promise into real patient outcomes and the potential for durable shareholder value growth.”

Christopher Anzalone, Ph.D., President and CEO

“I believe we approach 2027 with the strongest combination of near-term commercial opportunity and scientific capability in our history.”

Christopher Anzalone, Ph.D., President and CEO
4:01 PM ET 10-Q
Financial Results Kidz AI Inc. KIDZ

Kidz AI Q3 2026 Results: Net Loss of $654K

KIDZ AI Inc. reported a significant net loss of $7.34 million for the nine months ended September 30, 2026, compared to a $1.64 million loss in the prior year, driven by a $3.38 million fair value loss on crypto assets. Despite the loss, the company significantly strengthened its balance sheet through $10.74 million in private placement capital contributions and the conversion of $9.46 million in debt into equity.

Key figure
Net loss $654K
4:01 PM ET 10-K
Financial Results Hartford Creative Group, Inc. HFUS

Hartford Creative Group FY 2026 Results: Net Income $642K, Down 41.6% YoY

Hartford Creative Group reported total revenues of $2,744,029 for fiscal 2026, a 35% increase driven by its advertising agency business, though net income fell 42% to $641,767 due to a significant credit loss expense and higher income taxes. The company is pivoting toward a mini-drama platform (YYYS App) and is pursuing an uplisting to the Nasdaq Capital Market to fund its estimated $2.0 million in upcoming capital requirements.

Key figure
Net income $642K · -41.6% YoY
4:01 PM ET Form 4
Insider Buying Drilling Tools International Corp DTI

Drilling Tools International Director Jack D. Furst Buys $23.8K of Stock

Jack D. Furst, Director, bought 14,441 shares of Drilling Tools International Corp at $1.65 a share, worth $23.8K in total on Nov 11, 2026. Shares held after the trade: 77,920 (+22.7%).

Value
$23.8K
Shares
14,441
Price
$1.65
Role
Director
Holding change
+22.7%
Trade date
Nov 11, 2026
4:01 PM ET 10-Q
Financial Results Axt Inc AXTI

Axt Q3 2026 Results: Turns Profitable, Net Income $25.7M

AXT, Inc. reported a significant revenue increase to $73.4 million for the third quarter of 2026, up from $28.0 million in the prior year, driven by improved gross margins and operational performance. The company swung to a net income of $25.7 million for the quarter compared to a net loss of $1.9 million in 2025, while its cash position strengthened substantially to $485.5 million following a major common stock issuance.

Key figure
Net income $25.7M
4:01 PM ET 10-Q
Financial Results Akari Therapeutics Plc AKTX

Akari Therapeutics Q3 2026 Results: Net Loss of $4.84M, Loss Narrows

For the nine months ended September 30, 2026, Akari Therapeutics reported a net loss of $24.1 million, significantly higher than the $12.0 million loss in the prior year period, primarily driven by $12.1 million in impairment losses on goodwill and intangible assets. The company maintained a cash balance of $5.7 million and saw its total shareholders' equity decrease from $28.3 million to $17.5 million during the period.

Key figure
Net loss $4.84M
4:01 PM ET 10-Q
Financial Results Intellinetics, Inc. INLX

Intellinetics Q3 2026 Results: Net Loss of $239K, Loss Narrows

Intellinetics, Inc. reported a decrease in total assets from $17.3 million at year-end 2025 to $16.7 million as of September 30, 2026. The company's accumulated deficit increased to $26.0 million, while deferred revenues grew significantly to $4.1 million, reflecting shifts in its software-as-a-service and recurring revenue model.

Key figure
Net loss $239K
4:01 PM ET 10-Q
Financial Results EagleRock Land, LLC EROK

EagleRock Land Q3 2026 Results: Net Income $2.11M

EagleRock Land, LLC is an emerging growth company focused on surface, resource, and water infrastructure assets in the Permian Basin. The filing highlights its recent initial public offering in May 2026 and outlines key operational risks including customer concentration, commodity price volatility, and reliance on surface use agreements.

Key figure
Net income $2.11M
4:01 PM ET 10-Q
Financial Results Yale Transaction Finders, Inc. YTFD

Yale Transaction Finders Q3 2026 Results: Net Loss of $5.61K, Loss Narrows

Yale Transaction Finders, Inc. is a shell company with no revenue, reporting a net loss of $23,521 for the nine months ended September 30, 2026. The company faces substantial doubt about its ability to continue as a going concern, characterized by an accumulated deficit of $1,421,109 and reliance on related-party financing.

Key figure
Net loss $5.61K
4:01 PM ET Form 4
Insider Selling TheRealReal, Inc. REAL

TheRealReal CAO Steve Ming Lo Sells $299K of Stock

Steve Ming Lo, CAO, sold 20,070 shares of TheRealReal, Inc. at $14.90 a share, worth $299K in total on Nov 10, 2026. Shares held after the trade: 156,840 (-11.3%).

Value
$299K
Shares
20,070
Price
$14.90
Role
CAO
Holding change
-11.3%
Trade date
Nov 10, 2026
4:01 PM ET 10-Q
Financial Results Sellas Life Sciences Group, Inc. SLS

Sellas Life Sciences Group Q3 2026 Results: Net Loss of $10.1M, Loss Widens

SELLAS Life Sciences Group reported a net loss of $10.1 million for the third quarter of 2026, compared to $6.8 million in the prior year period, driven by increased research and development expenses. The company strengthened its balance sheet significantly, ending the period with $134.7 million in cash and cash equivalents following substantial warrant exercises during the nine months ended September 30, 2026.

Key figure
Net loss $10.1M
4:00 PM ET Form 4
Insider Selling Corvel Corp CRVL

Corvel Insider R. Judd Jessup Sells $576K of Stock

R. Judd Jessup sold 6,939 shares of Corvel Corp at $83.01 a share, worth $576K in total on Nov 9, 2026. Shares held after the trade: 104,859 (-6.2%).

Value
$576K
Shares
6,939
Price
$83.01
Holding change
-6.2%
Trade date
Nov 9, 2026
4:00 PM ET 8-K
Financial Results Kodiak Sciences Inc. KOD

Kodiak Sciences Financial Results

Kodiak Sciences reported Q3 2026 financial results and provided updates on its late-stage retinal pipeline, including positive Phase 3 DAYBREAK results for Zenkuda and tabirafusp-ted. The company plans to submit a multi-indication BLA for Zenkuda by the end of 2026 and expects pivotal data for KSI-101 in December 2026.

“We believe Kodiak stands apart in retina, with three late-stage assets that together give us the opportunity to build a leading retinal medicines company.”

Victor Perlroth, M.D., Chief Executive Officer of Kodiak Sciences

“Looking ahead, we expect to announce the first Phase 3 KSI-101 results in December and, if successful, plan to file a BLA for KSI-101 in the second quarter of 2027. We are also on track to submit the multi-indication BLA for Zenkuda by year end, supported by five successful Phase 3 studies.”

Victor Perlroth, M.D., Chief Executive Officer of Kodiak Sciences
4:00 PM ET Form 4
Insider Selling Amylyx Pharmaceuticals, Inc. AMLX

Amylyx Pharmaceuticals CFO James M. Frates Sells $1.21M of Stock

James M. Frates, CFO, sold 40,000 shares of Amylyx Pharmaceuticals, Inc. at $29.39 to $30.97 a share (average $30.19) in 4 transactions, worth $1.21M in total between Nov 9, 2026 and Nov 10, 2026. Shares held after the trade: 233,625 (-3.0%).

Value
$1.21M
Shares
40,000
Average price
$30.19
Role
CFO
Holding change
-3.0%
Trade date
Nov 9, 2026 to Nov 10, 2026
4:00 PM ET Form 4
Insider Selling Amylyx Pharmaceuticals, Inc. AMLX

Amylyx Pharmaceuticals Co-CEO Joshua B. Cohen Sells $2.98M of Stock

Joshua B. Cohen, Co-CEO, sold 100,000 shares of Amylyx Pharmaceuticals, Inc. at $29.39 to $30.11 a share (average $29.84) in 2 transactions, worth $2.98M in total on Nov 9, 2026. Shares held after the trade: 3,513,123 (-1.7%).

Value
$2.98M
Shares
100,000
Average price
$29.84
Role
Co-CEO
Holding change
-1.7%
Trade date
Nov 9, 2026
4:00 PM ET Form 4
Insider Selling Amylyx Pharmaceuticals, Inc. AMLX

Amylyx Pharmaceuticals Co-CEO Justin B. Klee Sells $2.98M of Stock

Justin B. Klee, Co-CEO, sold 100,000 shares of Amylyx Pharmaceuticals, Inc. at $29.39 to $30.11 a share (average $29.84) in 2 transactions, worth $2.98M in total on Nov 9, 2026. Shares held after the trade: 3,513,056 (-1.7%).

Value
$2.98M
Shares
100,000
Average price
$29.84
Role
Co-CEO
Holding change
-1.7%
Trade date
Nov 9, 2026
3:57 PM ET 10-Q
Financial Results Stone Point Credit Corp

Stone Point Credit Q3 2026 Results: Net Income $25.2M, Down 21.3% YoY

Stone Point Credit Corp reported a net increase in net assets from operations of $60.2 million for the nine months ended September 30, 2026, down from $95.2 million in the prior year period. The decrease was primarily driven by $29.6 million in net unrealized depreciation, while net investment income remained relatively stable at $89.3 million.

Key figure
Net income $25.2M · -21.3% YoY
3:57 PM ET 8-K
Loan & Debt Federal Home Loan Bank of Topeka

Federal Home Loan Bank of Topeka $3.29B Debt Financing with Office of Finance

Federal Home Loan Bank of Topeka issued $3.285 billion in consolidated obligation bonds and notes between November 9 and November 10, 2026. These debt securities are the joint and several obligations of the eleven Federal Home Loan Banks and are used to fund the bank's operations. The issuances include both fixed-rate and variable-rate instruments with maturities ranging from March 2027 to November 2028.

Value
$3.29B
Counterparty
Office of Finance
Term
through Nov 2028
3:51 PM ET 10-Q
Financial Results Brookfield Real Estate Income Trust Inc.

Brookfield Real Estate Income Trust Q3 2026 Results: Turns Profitable, Net Income $2.97M

For the nine months ended September 30, 2026, Brookfield Real Estate Income Trust reported total revenues of $121.4 million, up from $107.8 million in the prior year period. Net income for the nine-month period was $8.7 million, though the company recorded a net loss attributable to stockholders of $0.37 million after accounting for non-controlling interests.

Key figure
Net income $2.97M
3:51 PM ET 10-Q
Financial Results Fundrise eREIT, LLC

Fundrise eREIT Q3 2026 Results: Net Loss of $11.3M

Fundrise eREIT, LLC reported a significant net loss of $11.3 million for Q3 2026, compared to a net income of $5.7 million in the prior year, primarily driven by losses in equity method investees. The company underwent a major merger during the period, resulting in total assets increasing from $274.9 million at year-end 2025 to $791.6 million by September 30, 2026.

Key figure
Net loss $11.3M
3:50 PM ET 10-Q
Financial Results Federal Home Loan Bank of Dallas

Federal Home Loan Bank of Dallas Q3 2026 Results: Net Income $111M, Down 29.3% YoY

For the nine months ended September 30, 2026, the Federal Home Loan Bank of Dallas reported net income of $356.2 million, a decrease from $456.3 million in the prior year period, primarily driven by lower net interest income. Total assets decreased slightly to $106.8 billion from $108.5 billion at year-end 2025, while total capital increased to $6.87 billion.

Key figure
Net income $111M · -29.3% YoY
3:48 PM ET 10-Q
Financial Results Prosper Funding LLC

Prosper Funding Q3 2026 Results: Turns Profitable, Net Income $41.7M

Prosper Marketplace, Inc. and Prosper Funding LLC filed a combined Form 10-Q for the period ending September 30, 2026, reporting 79,938,949 shares of PMI common stock outstanding. The filing highlights significant risks including the impact of a September 2025 cybersecurity incident and the termination of several variable interest entities such as PMIT 2023-1 and PMIT 2024-1.

Key figure
Net income $41.7M
3:48 PM ET 10-Q
Financial Results Prosper Marketplace, Inc

Prosper Marketplace Q3 2026 Results: Turns Profitable, Net Income $41.7M

Prosper Marketplace, Inc. reported cash and cash equivalents of $74.1 million as of September 30, 2026, an increase from $46.8 million at year-end 2025. The filing highlights a significant cybersecurity incident from September 2025 and notes that there were 79,938,949 shares of common stock outstanding as of November 9, 2026.

Key figure
Net income $41.7M
3:47 PM ET 8-K
Shareholder Meeting Ribbon Acquisition Corp. RIBB

Ribbon Acquisition Shareholder Meeting

Ribbon Acquisition Corp. announced the cancellation of its Extraordinary General Meeting of Shareholders, which was originally scheduled for November 13, 2026. As a result of the cancellation, the meeting will not be held and no shareholder proposals will be submitted for a vote.

3:46 PM ET 10-Q
Financial Results Lord Abbett Private Credit Fund S

Lord Abbett Private Credit Fund S Q3 2026 Results: Net Income $4.79M, Up 87.9% YoY

For the nine months ended September 30, 2026, Lord Abbett Private Credit Fund S reported total investment income of $28.63 million and net investment income of $12.69 million. Total net assets grew to $226.77 million from $127.42 million at the end of 2025, driven by significant capital raises, though the net asset value per share decreased slightly from $25.11 to $24.68.

Key figure
Net income $4.79M · +87.9% YoY
3:46 PM ET 10-Q
Financial Results Rreef Property Trust, Inc. ZRPTIX

Rreef Property Trust Q3 2026 Results: Net Loss of $2.6M

RREEF Property Trust reported a net loss of $2.6 million for the quarter ended September 30, 2026, compared to a net income of $22.1 million in the prior year period, primarily due to a $8.3 million impairment provision and lower gains on real estate sales. Total assets decreased to $298.5 million from $372.5 million at year-end 2025 as the company continued to sell real estate assets and pay down debt.

Key figure
Net loss $2.6M
3:44 PM ET 10-Q
Financial Results Fortress Credit Realty Income Trust

Fortress Credit Realty Income Trust Q3 2026 Results: Net Income $28.8M, Up 56.1% YoY

Fortress Credit Realty Income Trust reported a significant increase in its share count across multiple classes as of November 12, 2026, with Class B and Class J-1 shares being the largest components. The filing highlights risks related to interest rate fluctuations, real estate market conditions, and the company's status as an emerging growth company and non-accelerated filer.

Key figure
Net income $28.8M · +56.1% YoY
3:44 PM ET 10-Q
Financial Results Lord Abbett Private Credit Fund

Lord Abbett Private Credit Fund Q3 2026 Results: Net Income $21.8M, Up 80.7% YoY

For the nine months ended September 30, 2026, Lord Abbett Private Credit Fund reported total investment income of $111.2 million and net investment income of $58.7 million. Total net assets grew to $869.4 million from $528.0 million at the end of 2025, despite a net decrease in unrealized appreciation of $7.0 million during the period.

Key figure
Net income $21.8M · +80.7% YoY

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.